Galmed Pharmaceuticals
GLMD
22 hedge funds and large institutions have $14.6M invested in Galmed Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 7 closing their positions.
0% less ownership
Funds ownership: 0.02% → 0.01% (-0%)
15% less funds holding
Funds holding: 26 → 22 (-4)
25% less capital invested
Capital invested by funds: $19.4M → $14.6M (-$4.79M)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
58% less call options, than puts
Call options by funds: $81K | Put options by funds: $194K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$178K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$117K |
| 3 |
BAM
Brave Asset Management
Summit,
New Jersey
|
+$34.8K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$34.8K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$30.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
II
Ibex Investors
Denver,
Colorado
|
-$918K |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$813K |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$634K |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$292K |
| 5 |
Renaissance Technologies
New York
|
-$208K |
GLMD Hedge Fund Activity: Q2 2021 in Review
22 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q2 2021, worth a combined $14.6M — down 25% from $19.4M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of GLMD and 3 opened new positions — a net loss of 4 holders — while 7 trimmed existing stakes and 3 added.
The largest buyer was Raymond James & Associates, adding an estimated $178K. The largest seller was Ibex Investors, cutting an estimated $918K.
- 22 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q2 2021, down from 26 in Q1 2021.
- Funds reported $14.6M of Galmed Pharmaceuticals stock for Q2 2021, down 25% quarter-over-quarter.
- 3 funds opened new Galmed Pharmaceuticals positions in Q2 2021 and 7 closed out, a net change of -4 holders.
- The largest Galmed Pharmaceuticals buyer in Q2 2021 was Raymond James & Associates, an estimated $178K added.
- The largest Galmed Pharmaceuticals seller in Q2 2021 was Ibex Investors, an estimated $918K sold.
Based on aggregated 13F filings for Q2 2021.